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the association between NLR and lymph node metastasis, 
muscle-invasive and non-organ-confined disease. The asso-
ciation of altered NLR with recurrence-free survival (RFS) 
and cancer-specific survival (CSS) was evaluated using 
Cox proportional hazards regression models.
Results Altered NLR was observed in 1428 (62.8 %) 
patients and associated with more advanced pathologi-
cal tumor stage, lymph node metastasis, lymphovascu-
lar invasion, tumor necrosis and sessile tumor architec-
ture. In a preoperative model that included age, gender, 
tumor location and architecture, NLR was an independent 
predictive factor for the presence of lymph node metas-
tasis, muscle-invasive and non-organ-confined disease 
Abstract 
Objective Several retrospective studies with small cohorts 
reported neutrophil-to-lymphocyte ratio (NLR) as a prog-
nostic marker in upper tract urothelial carcinoma (UTUC) 
following radical nephroureterectomy (RNU). We aimed at 
validating the predictive and prognostic role of NLR in a 
large multi-institutional cohort.
Methods Preoperative NLR was assessed in a multi-
institutional cohort of 2477 patients with UTUC treated 
with RNU. Altered NLR was defined by a ratio >2.7. 
Logistic regression analyses were performed to assess 
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(p < 0.001). Within a median follow-up of 40 months (IQR 
20–76 months), 548 (24.1 %) patients experienced disease 
recurrence and 453 patients (19.9 %) died from their can-
cer. Compared to patients with normal NLR, those with 
altered NLR had worse RFS (0.003) and CSS (p = 0.002). 
In multivariable analyses that adjusted for the effects of 
standard clinicopathologic features, altered NLR did not 
retain an independent value. In the subgroup of patients 
treated with lymphadenectomy in addition to RNU, NLR 
was independently associated with CSS (p = 0.03).
Conclusion In UTUC, preoperative NLR is associated 
with adverse clinicopathologic features and independently 
predicts features of biologically and clinically aggressive 
UTUC such as lymph node metastasis, muscle-invasive or 
non-organ-confined status. NLR may help better risk strat-
ify patients with regard to lymphadenectomy and conserva-
tive therapy.
Keywords Neutrophil-to-lymphocyte ratio · Prognostic 
factor · Urothelium · Carcinoma · Recurrence · Death
Introduction
Upper tract urothelial carcinoma (UTUC) is a relatively 
rare disease with an annual incidence of 1–2 cases per 
100,000 inhabitants [1]. Despite intense collaborative 
efforts to improve the knowledge of this disease, its man-
agement remains challenging [2]. The preoperative staging 
is therefore a major concern in UTUC since current imag-
ing has still limited accuracy. Current predictive models 
based on preoperative parameters propose risk stratifica-
tion on low-risk and high-risk tumors. These models may 
guide physicians for treatment decision making regarding 
the completion of a kidney-sparing procedure or a radical 
nephroureterectomy (RNU) with or without lymphadenec-
tomy. RNU is indeed the standard treatment for high-risk 
UTUC. However, up to 30 % of the patients will experi-
ence early tumor recurrence after radical treatment and 
80 % of these patients will eventually die from their disease 
[3, 4]. The prediction of oncologic outcomes is, therefore, 
another major concern in UTUC. The established prognos-
tic models for UTUC mainly rely on definitive pathological 
features such as T stage, architecture, lymphovascular inva-
sion, tumor location and concomitant in situ carcinoma [5]. 
However, these predictive and prognostic models need fur-
ther optimization and further studies are needed to identify 
and validate new preoperative factors. Current efforts are 
focusing on biological and clinical biomarkers that capture 
the tumor behavior and reflect its intrinsic aggressiveness.
Markers of inflammatory response have been reported 
as potential biomarkers of tumor aggressiveness and worse 
outcome in several malignancies [6]. Indeed, tumor cells 
interact with their microenvironment and enhance local 
inflammation by releasing different cytokines and inter-
leukins [7]. Such inflammatory setting could favor tumor 
progression while modifying levels of routine blood param-
eters such as C-reactive protein (CRP), leukocytes and 
derivatives. Several studies reported neutrophil-to-lym-
phocyte ratio (NLR), that combines neutrophils and lym-
phocytes, as a predictive factor for the presence of lymph 
node metastasis or non-organ-confined (NOC) disease in 
vulva squamous cell carcinoma [8] and in bladder cancer 
[9], respectively. Other studies demonstrated its prognos-
tic value in pancreatic cancer, colon cancer or breast can-
cer [10]. In urological neoplasms, its prognostic value has 
been also reported in bladder cancer [11] and renal cell car-
cinoma [12]. In UTUC, evidence regarding its prognostic 
value is, however, limited to recent retrospective studies 
with relatively small cohorts [13–15], and none is known 
about its ability to predict adverse pathological features.
The aim of the present study was to externally validate 
the predictive and prognostic significance of pretreatment 
NLR in a large multi-institutional cohort from the UTUC 
collaboration.
Patients and methods
Patient selection and data collection
This study obtained an institutional review board approval 
in each institution, with all participating sites providing 
institutional data sharing agreements prior to the initia-
tion of the study. 2477 patients treated with RNU for non-
distant metastatic UTUC (Ta-T4N0-1M0) between March 
1990 and May 2008 at institutions from the international 
UTUC collaboration were included. Patients with sys-
temic diseases that could interfere with NLR at the time 
of RNU (such as leukemia, lymphoma, chronic inflamma-
tory diseases, or autoimmune diseases), missing data or a 
follow-up <3 months (n = 203) were excluded. No patient 
received neoadjuvant chemotherapy.
Study variables
Pretreatment NLR was assessed within the 30 days prior 
to RNU and defined as altered if ratio >2.7. This cutoff 
was based on previously published results [14]. Demo-
graphical, surgical, pathological, NLR (categorically coded 
according to cutoff) and outcomes data were collected and 
entered in a computerized database. Histology, tumor stage, 
grade, location, architecture, presence of lymphovascu-
lar invasion (LVI), tumor necrosis and carcinoma in situ 
(CIS) were confirmed by blinded re-review of the original 
pathology slides. The 2002 American Joint Committee on 
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Cancer—Union International Centre le Cancer (AJCC-
UICC) Tumor–Node–Metastasis (TNM) classification and 
the 1998 WHO/International Society of Urologic Pathol-
ogy (ISUP) consensus classification were used for patho-
logic staging and grading, respectively.
Management and follow‑up
All patients had a standard RNU with bladder cuff removal 
with curative intent. A regional lymphadenectomy and 
adjuvant chemotherapy were completed at the discretion 
of the urologist. Follow-up was done according to institu-
tional protocols in agreement with local guidelines at the 
time. Generally, patients were seen postoperatively quar-
terly for the first year, semiannually in the second year, and 
annually thereafter. Follow-up visits consisted of a physical 
examination, serum chemistry evaluation, urinary cytology 
and endoscopic examination of the bladder. A chest radi-
ography and diagnostic imaging of the contralateral upper 
urinary tract, with a computerized tomography urogram, an 
ultrasonography and/or an intravenous pyelography, were 
performed annually. Chest computerized tomography and 
bone scan were performed at the discretion of the physi-
cians. Recurrence was defined as any local recurrence (in 
the retroperitoneum or renal fossa) or distant metastasis. 
Recurrences in the bladder or contralateral upper urinary 
tract were considered as second primaries. Outcomes were 
measured by time to disease recurrence or to cancer-spe-
cific death. Cause of death was determined by the treating 
physician, based on chart review corroborated by death cer-
tificates, or by death certificates alone [16].
Statistical analysis
Associations of NLR with categorical variables were 
assessed using Chi-square tests, while differences in con-
tinuous variables were analyzed using Kruskal–Wallis tests. 
Kaplan–Meier method was used to estimate recurrence-free 
survival (RFS) and cancer-specific survival (CSS); log-rank 
tests were applied for pair-wise comparison of survival. 
Muscle-invasive disease was defined as ≥pT2 and/or N+ 
disease, while NOC as ≥pT3 and/or N+ disease. Logistic 
regression analysis was performed to assess the associa-
tion of NLR and other predictive factors with lymph node 
metastasis, muscle-invasive and NOC disease. Accuracy of 
the models was calculated using receiver operating char-
acteristic (ROC) analysis. Univariable and multivariable 
Cox regression models addressed associations of RFS and 
CSS with potential prognostic factors. Subgroup analyses 
were done for patients with pTa-2 N0/Nx, pT1-3 N0/Nx, 
pT3/pT4 N0/Nx disease, high-grade tumors, positive and 
negative lymph node metastases or, treated with or without 
lymphadenectomy or adjuvant chemotherapy. All p values 
were two-sided, and statistical significance was defined as 
a p < 0.05. Statistical analyses were performed using Stata 
11.0 statistical software (Stata Corp., College Station, TX, 
USA).
Results
Descriptive characteristics and association with altered 
NLR
Table 1 summarizes clinicopathologic characteristics of 
the cohort. A regional lymphadenectomy was performed 
in 729 patients (32.1 %). Adjuvant chemotherapy was 
administered in 217 patients (9.5 %). Altered NLR was 
observed in 1428 patients (62.8 %) and was associated with 
more advanced pathological tumor stage (p < 0.001), LVI 
(p < 0.001), tumor necrosis (p < 0.001), sessile architec-
ture (p < 0.001) and lymph node metastases (p < 0.001) 
(Table 1).
Association of NLR with high‑risk disease and lymph 
node metastasis
In univariable analysis, NLR was a predictive factor for 
lymph node metastasis, muscle-invasive and NOC disease 
(p ≤ 0.001, each) (Table 2). Similarly, kidney location and 
sessile architecture were independent predictors. In multi-
variable analysis that adjusted for the effects of age, gen-
der, location and architecture, NLR retained an independ-
ent value for the prediction of all three pathologic features 
(p < 0.001, each). Addition of NLR improved by 2 points 
the accuracies of the models that predicted muscle-invasive 
and NOC disease (accuracy: 68 and 72 %, respectively) 
and 1 point the one dedicated to the prediction of the lymph 
node metastatic status (accuracy = 68 %).
Association of NLR with cancer recurrence 
and cancer‑specific survival
Within a median follow-up of 40 months (range 
20–76 months), 548 patients (24.1 %) experienced disease 
recurrence and 453 patients (19.9 %) died from their cancer. 
Patients with altered NLR had worse RFS and CSS than those 
with normal NLR (p < 0.003 and p = 0.002, respectively). 
3-year RFS and CSS estimates were: 78 (CI 76.9–82.7 %) 
and 85.8 % (CI 83–88.2 %) for patients with normal NLR, 
and 74.5 (CI 72.0–76.9 %) and 81.1 % (CI 78.8–83.3 %) for 
patients with abnormal NLR, respectively (Fig. 1a, b).
Table 3 shows the univariable and multivariable Cox 
proportional hazard regression analyses in the overall 
cohort. In univariable analysis, altered NLR was sig-
nificantly associated with RFS and CSS (HR = 1.30; 
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p = 0.003 and HR = 1.36; p = 0.002, respectively); how-
ever, when adjusted for the effects of clinicopathologic fea-
tures, NLR did not retain its statistical significance for both 
endpoints (HR = 1.05; p = 0.59 and HR = 1.07; p = 0.48, 
respectively). Similar results were observed in all subgroup 
analyses performed according to T stage, grade, lymph 
node status or adjuvant chemotherapy (Table 4).
Association of NLR with cancer recurrence 
and cancer‑specific survival after RNU 
with lymphadenectomy
The median number of lymph nodes removed during lym-
phadenectomy was 5 (IQR 2–10). Among the patients 
treated with lymphadenectomy, 239 (32.8 %) experienced 
Table 1  Association of 
neutrophil-to-lymphocyte ratio 
(NLR) and clinicopathologic 
characteristics in 2274 
patients treated with radical 
nephroureterectomy for upper 
tract urothelial carcinoma
Statistically significant results are shown in bold
All patients Normal NLR Altered NLR p
Total, n (%) 2274 846 (37.2) 1428 (62.8)
Age 0.66
 Median (IQR) 69 (61–76) 69 (61–76) 70 (62–76)
Gender, n (%) 0.31
 Male 1527 (67.1) 579 (68.1) 948 (66.4)
 Female 747 (32.9) 267 (31.9) 480 (33.6)
Tumor stage, n (%) <0.001
 pTa 497 (21.8) 199 (23.5) 298 (20.9)
 pTis 48 (2.2) 19 (2.2) 29 (2.3)
 pT1 532 (23.4) 244 (28.8) 288 (20.0)
 pT2 441 (19.4) 150 (17.8) 291 (20.3)
 pT3 671 (29.5) 217 (25.7) 454 (31.8)
 pT4 85 (3.7) 17 (2.0) 68 (4.7)
Grade, n (%) 0.22
 Low 367 (16.14) 147 (17.3) 220 (15.4)
 High 1907 (83.86) 699 (82.7) 1208 (84.6)
Lymph node status, n (%) 0.001
 pNx 1545 (68.0) 570 (67.4) 975 (68.2)
 pN0 545 (23.9) 228 (27.0) 317 (22.2)
 pN1 184 (8.1) 48 (5.6) 136 (9.6)
Lymphovascular invasion, n (%) <0.001
 Yes 499 (21.9) 143 (16.9) 356 (24.9)
 No 1775 (78.1) 703 (83.1) 1072 (75.1)
Concomitant carcinoma in situ, n (%) 0.17
 Yes 528 (23.2) 183 (21.6) 345 (24.1)
 No 1746 (76.8) 663 (78.4) 1083 (75.9)
Multifocality, n (%) 0.16
 Yes 538 (23.7) 214 (25.3) 324 (22.7)
 No 1736 (76.3) 632 (74.7) 1104 (77.3)
Necrosis, n (%) <0.001
 Yes 516 (22.7) 129 (15.2) 387 (27.1)
 No 1758 (77.3) 717 (84.8) 1041 (72.9)
Architecture, n (%) 0.001
 Papillary 1751 (77.0) 684 (80.9) 1067 (74.8)
 Sessile 523 (23.0) 162 (19.2) 361 (25.2)
Location 0.67
 Kidney 1448 (63.7) 534 (63.1) 914 (64.0)
 Ureter 826 (36.3) 312 (36.9) 514 (36.0)
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tumor recurrence and 192 (26.3 %) died from the disease. 
NLR was altered in 170 (71.1 %) and 141 (73.4 %) patients, 
respectively. On Kaplan–Mayer analysis, altered NLR was 
associated with both worse RFS and CSS (p < 0.001, each). 
3-year RFS and CSS were 62.1 and 72.9 % in patients with 
altered NLR, compared to 73.9 and 84 % in patients with 
normal NLR (Fig. 1c, d). NLR was associated with RFS 
(HR 1.63; IC 1.23–2.16, p < 0.001) and CSS (HR 1.79; 
IC 1.30–2.47, p < 0.001) on univariable analyses. When 
adjusted for the effects of clinicopathologic features, NLR 
retained its statistical significant association with CSS (HR 
1.43; IC 1.02–2.00, p = 0.03), but not with RFS (HR 1.29; 
IC 0.96–1.73, p = 0.08) (Table 5).
Discussion
In the present study, we assessed the significance of preop-
erative NLR in a large multi-institutional cohort of patients 
with UTUC treated by RNU. We demonstrated that abnor-
mal NLR was not only associated with adverse pathological 
features and worse oncologic outcomes, but also predicted 
the presence of lymph node metastases, muscle-invasive 
and NOC disease. Therefore, the potential of NLR could 
be in the preoperative clinical decision making regarding 
lymphadenectomy indication and extent, and patient coun-
seling regarding conservative therapy.
Using a ratio of 2.7, we observed that almost two-thirds 
of the patients had an altered preoperative NLR. Altered 
NLR was associated with features of biologically and clini-
cally aggressive UTUC such as advanced tumor stage, LVI, 
tumor necrosis, sessile architecture and lymph node metas-
tases. These findings confirm the results reported in smaller 
cohorts [13–15]. The potential reasons for such asso-
ciations remain hypothetical. NLR could reflect a balance 
between neutrophilia and lymphopenia that results from the 
relationship between the immune system and tumorigen-
esis. On the one hand, the secretion of granulocyte colony-
stimulating factor (G-CSF) by tumor cells may promote 
neutrophils production in bone marrow and recruitment of 
the neutrophils in the tumor environment. De Larco et al. 
[7] showed that these “tumor-associated neutrophils” could 
have a role in the tumor microenvironment and local angio-
genesis. Neoangiogenesis could therefore promote tumor 
progression and migration of tumor cells. On the other 
hand, lymphopenia may be responsible for poor immune 
response against tumor and favor tumor aggressiveness and 
progression [17]. Even if this association is of great inter-
est, it does not ensure the independent value of NLR to pre-
dict adverse pathological features at final pathology.
We demonstrated, therefore, the ability of NLR to inde-
pendently predict lymph node metastasis, muscle-invasive 
and NOC disease in a preoperative model that included Ta
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patient age, gender, tumor location and architecture. This 
preoperative model may help physicians identify patients 
who should be proposed a radical treatment with RNU or a 
lymphadenectomy during RNU [18]. Previous models have 
been proposed to identify such patients and adapt clinical 
decision making [19–21]. Margulis et al. [19] developed a 
model to predict muscle-invasive disease using preopera-
tive clinicopathologic features such as age, gender, tumor 
location, architecture and grade at biopsy. Another predic-
tive model combined high grade, tumor location, local inva-
sion and hydronephrosis on imaging and achieved 71 and 
70 % accuracies for predicting muscle-invasive and NOC 
disease, respectively [20]. We constructed a model includ-
ing NLR but did not consider, however, grade at biopsy and 
data from the preoperative imaging. Our model only relies 
on easy accessible factors and demonstrates accuracies of 
68–72.5 % for the prediction of NOC, muscle-invasive or 
positive lymph node disease. Further improvement of these 
models may be obtained, however, by the combination of 
NLR with other routinely available biomarkers as CRP 
[22].
We demonstrated NLR was associated with worse onco-
logic outcomes such as RFS and CSS. However, adjusted 
for standard pathologic prognostic factors in UTUC, NLR 
did not retain statistical significance. Most of the previous 
studies reported, however, independent predictive value for 
RFS [15], CSS [13, 14] and OS [14]. The discrepancies 
between these studies and our findings could be explained 
by several reasons. First, initial studies defined the optimal 
cutoff for NLR as 2.7 [14] or 3 [13] based on the interpre-
tations of iterative Cox or ROC analysis observed in the 
cohorts. Only one study externally validated the prognos-
tic value of NLR using a predefined threshold of 3 [15]. 
To our knowledge, we are the first to propose an external 
validation with the 2.7 cutoff proposed by Dalpiaz et al. 
[14]. Second, the parameters used in multivariable analy-
sis proposed in these studies varied widely. For example, 
Tanaka et al. only adjusted on age, N status, stage and LVI. 
Fig. 1  Kaplan–Meier estimates of recurrence-free survival and can-
cer-specific survival stratified by NLR status in 2274 patients with 
UTUC treated with RNU alone (a, b, respectively), and 729 patients 
with UTUC treated with RNU and lymphadenectomy (c, d, respec-
tively). RFS recurrence-free survival, CSS cancer-specific survival, 
CI confidence interval, NLR neutrophil-to-lymphocyte ratio, UTUC 
upper tract urothelial carcinoma, RNU radical nephroureterectomy
127World J Urol (2017) 35:121–130 
1 3
We performed a multivariable analysis using most of the 
clinicopathologic parameters published in the literature 
[3, 23, 24]. When we limited our multivariable analysis to 
the parameters used in established prognostic models [3, 
23–25], NLR did not demonstrate independent prognostic 
value, however (data not shown). Third, populations were 
different regarding the clinicopathologic characteristics. 
Luo et al. [13] only included patients with pT stage <4 and 
Table 3  Univariable and multivariable Cox regression analyses predicting recurrence and cancer-specific mortality of 2274 patients treated with 
radical nephroureterectomy for upper tract urothelial carcinoma
CI confidence interval, HR hazard ratio, NLR neutrophil-to-lymphocyte ratio
Recurrence-free survival Cancer-specific survival
Univariable Multivariable Univariable Multivariable
HR 95 % CI p value HR 95 % CI p value HR 95 % CI p value HR 95 % CI p value
Age 1.01 1.00–1.02 <0.001 1.01 1.00–1.02 0.001 1.02 1.01–1.03 <0.001 1.02 1.01–1.03 <0.001
Gender 1.10 0.92–1.31 0.27 1.01 0.84–1.21 0.89 1.06 0.87–1.29 0.52 0.94 0.77–1.15 0.58
Stage
 Ta Ref.
 Tis 2.98 1.30–6.83 0.01 1.61 0.94–7.25 0.066 3.58 1.44–8.88 0.006 3.37 1.08–10.56 0.03
 T1 2.16 1.38–3.37 <0.001 1.87 0.89–3.91 0.095 2.00 1.18–3.37 0.009 1.66 0.70–3.92 0.24
 T2 5.01 3.30–7.59 <0.001 3.84 1.86–7.92 <0.001 5.54 3.45–8.91 <0.001 4.11 1.79–9.45 <0.001
 T3 10.29 6.97–15.19 <0.001 6.96 3.40–14.21 <0.001 11.93 7.63–18.65 <0.001 7.85 3.45–17.88 <0.001
 T4 39.75 25.36–62.29 <0.001 19.94 9.26–42.96 <0.001 46.14 27.74–76.75 <0.001 21.30 8.86–51.22 <0.001
Grade 6.17 3.94–9.64 <0.001 1.10 0.48–2.50 0.81 6.93 4.14–11.60 <0.001 1.17 0.45–3.03 0.73
Lymphovascu-
lar invasion
3.13 2.64–3.71 <0.001 1.24 1.02–1.52 0.029 3.39 2.81–4.09 <0.001 1.35 1.08–1.67 0.006
Architecture 3.30 2.78–3.91 <0.001 1.37 1.12–1.66 0.002 3.46 2.87–4.17 <0.001 1.36 1.10–1.69 0.004
Carcinoma 
in situ
1.67 1.39–2.00 <0.001 1.23 1.01–1.50 0.035 1.57 1.28–1.92 <0.001 1.08 0.87–1.35 0.46
Necrosis 2.22 1.86–2.64 <0.001 0.98 0.81–1.19 0.90 2.25 1.86–2.74 <0.001 1.00 0.81–1.23 0.98
Multifocality 1.31 1.08–1.58 0.004 0.91 0.74–1.11 0.36 1.33 1.08–1.64 0.006 0.95 0.76–1.70 0.66
Location 1.11 0.94–1.32 0.19 1.31 1.09–1.57 0.003 1.16 0.96–1.40 0.11 1.39 1.14–1.70 <0.001
Lymph node 
metastases  
Nx
Ref.
 N0 1.13 0.92–1.40 0.22 0.91 0.73–1.12 0.39 0.99 0.77–1.26 0.94 0.77 0.60–0.98 0.04
 N1 5.26 4.25–6.51 <0.001 2.10 1.64–2.68 <0.001 5.24 4.16–6.59 <0.001 1.96 1.51–2.56 <0.001
NLR 1.30 1.09–1.56 0.003 1.05 0.87–1.26 0.59 1.36 1.11–1.66 0.002 1.07 0.87–1.31 0.48
Table 4  Univariable and multivariable Cox regression analyses for prediction of recurrence and cancer-specific mortality according NLR status 
in subgroups of patients treated with radical nephroureterectomy
CI confidence interval, HR hazard ratio
Patient subgroups Recurrence-free survival Cancer-specific survival
Univariable Multivariable Univariable Multivariable
HR 95 % CI p value HR 95 % CI p value HR 95 % CI p value HR 95 % CI p value
pTa-4 high grade 1.28 1.07–1.54 0.007 1.05 0.87–1.26 0.65 1.34 1.09–1.64 0.005 1.06 0.87–1.31 0.54
pTa-2 pN0/Nx 0.98 0.74–1.31 0.91 0.85 0.63–1.13 0.27 1.02 0.73–1.41 0.92 0.86 0.62–1.20 0.38
pT1-3 pN0/Nx 1.07 0.87–1.33 0.51 0.92 0.74–1.14 0.43 1.20 0.94–1.52 0.14 1.01 0.79–1.29 0.92
pT3/pT4 N0/Nx 1.16 0.87–1.53 0.31 1.12 0.84–1.49 0.44 1.26 0.92–1.72 0.1 1.20 0.87–1.64 0.27
pT2-4 pN0/Nx 1.08 0.86–1.36 0.51 1.01 0.80–1.28 0.90 1.11 0.86–1.43 0.40 1.03 0.80–1.33 0.82
pTa-4 pN0 1.30 0.90–1.89 0.16 1.17 0.79–1.74 0.42 1.69 1.07–2.67 0.02 1.47 0.91–2.38 0.1
pTa-4 pN1 1.54 0.99–2.39 0.05 1.30 0.81–2.09 0.27 1.39 0.88–2.19 0.15 1.20 0.73–1.98 0.46
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without lymph node metastases. Conversely, half cohort 
of Tanaka et al. [15] had locally advanced disease. How-
ever, none of the subgroup analyses we performed with 
advanced disease or localized disease demonstrated inde-
pendent prognostic value for NLR.
We demonstrated, however, that NLR would be an inde-
pendent prognostic factor regarding CSS in patients who were 
treated with lymphadenectomy. In previous studies, status 
of lymphadenectomy was not routinely performed [13–15]. 
Staging benefit of lymphadenectomy in UTUC is noteworthy 
[26]. Xylinas et al. [27] showed, therefore, that all patients 
treated with RNU for UTUC should receive LND to ensure 
accurate nodal staging. In the future, metastatic patients may 
also receive immune checkpoint inhibitors such as anti-PDL1. 
Preliminary results in bladder cancer suggest that circulat-
ing inflammatory markers may predict response to immune 
checkpoint inhibitors [28]. Therefore, NLR could be of great 
value in the identification of patients with metastatic status 
that may benefit from immune checkpoint inhibitors.
Although this is the largest study that investigated the 
predictive and prognostic value of pretreatment NLR 
with outcomes after RNU, our study has some limita-
tions that should be considered. First, its retrospective and 
multicentric status may be responsible for variations in 
laboratory, pathological and surgical workup that could con-
found the results. In the present study, NLR was determined 
preoperatively with a predefined cutoff and analyzed as a 
categorical variable. We did not complete these investiga-
tions with exact levels of NLR as neutrophils and lympho-
cytes counts were measured with different assays. Continu-
ously coded NLR or different thresholds may have provided 
different conclusions. Assessment of NLR at different 
points in time may also have excluded confounders, such 
as occult infectious diseases without any symptoms preop-
erative, autoimmune diseases responsible for temporally 
changes. Finally, we only investigated NLR. A growing evi-
dence suggests that derivatives of NLR or its combination 
with other preoperative markers of systemic inflammation 
may be helpful in the prediction of oncologic outcomes in 
UTUC and warrants further investigations [29–31].
Conclusion
In UTUC, NLR is associated with adverse clinicopatho-
logic features and worse oncologic outcomes. However, 
Table 5  Univariable and multivariable Cox regression analyses predicting the recurrence and cancer-specific mortality of 729 patients treated 
with radical nephroureterectomy and lymphadenectomy for upper tract urothelial carcinoma
Statistically significant results are shown in bold
CI confidence interval, HR hazard ratio, NLR neutrophil-to-lymphocyte ratio
Recurrence-free survival Cancer-specific survival
Univariable Multivariable Univariable Multivariable
HR 95 % CI p value HR 95 % CI p value HR 95 % CI p value HR 95 % CI p value
Age 1.01 1.00–1.02 0.01 1.01 0.99–1.02 0.06 1.02 1.00–1.03 <0.001 1.02 1.00–1.03 0.005
Gender 1.23 0.95–1.60 0.11 1.14 0.86–1.49 0.34 1.06 0.79–1.43 0.66 0.93 0.68–1.27 0.67
Stage
 Ta Ref.
 Tis 1.06 0.12–8.87 0.95 1.47 0.13–16.43 0.75 1.52 0.17–13.06 0.70 3.81 0.23–61.67 0.34
 T1 2.34 0.93–5.90 0.07 2.76 0.63–11.98 0.17 1.41 0.47–4.23 0.53 2.63 0.33–20.90 0.36
 T2 5.24 2.23–12.31 <0.001 5.37 1.28–22.42 0.02 4.34 1.69–11.13 0.002 6.64 0.89–49.14 0.06
 T3 10.22 4.50–23.17 <0.001 8.68 2.12–35.50 0.003 10.03 4.09–24.61 <0.001 12.34 1.70–84.46 0.01
 T4 32.13 13.57–76.07 <0.001 19.95 4.66–85.29 <0.001 33.0 12.90–84.60 <0.001 25.92 3.45–194.75 0.002
Grade 6.76 2.51–18.18 <0.001 0.73 0.13–4.04 0.72 5.30 1.97–14.29 <0.001 0.36 0.04–3.26 0.36
Lymphovascular  
invasion
2.45 1.90–3.16 <0.001 0.88 0.66–1.18 0.42 2.92 2.19–3.88 <0.001 1.05 0.76–1.45 0.74
Architecture 3.05 2.36–3.94 <0.001 1.48 1.10–2.00 0.009 3.39 2.55–4.52 <0.001 1.58 1.13–2.20 0.007
Carcinoma in situ 1.38 1.06–1.79 0.01 1.17 0.88–1.56 0.26 1.31 0.97–1.77 0.07 0.94 0.68–1.31 0.74
Necrosis 1.97 1.52–2.54 <0.001 1.02 0.77–1.35 0.85 1.97 1.48–2.62 <0.001 1.02 0.75–1.39 0.86
Multifocality 1.12 0.84–1.48 0.42 0.82 0.60–1.11 0.20 1.32 0.97–1.80 0.07 0.99 0.71–1.39 0.98
Location 0.97 0.74–1.27 0.87 1.23 0.93–1.64 0.13 1.02 0.76–1.37 0.87 1.31 0.95–1.79 0.09
Lymph node metastases 4.61 3.57–5.96 <0.001 2.62 1.95–3.52 <0.001 5.23 3.93–6.97 <0.001 2.75 1.98–3.83 <0.001
NLR 1.63 1.23–2.16 <0.001 1.29 0.96–1.73 0.08 1.79 1.30–2.47 <0.001 1.43 1.02–2.00 0.03
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its prognostic role may be limited to patients treated with 
lymphadenectomy. Conversely, all patients could benefit 
in the preoperative setting from its ability to independently 
predict lymph node metastasis, muscle-invasive and NOC 
disease. NLR may be therefore a useful biomarker in clini-
cal decision making regarding a radical treatment and the 
completion and extent of a lymphadenectomy.
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